<DOC>
	<DOC>NCT00170911</DOC>
	<brief_summary>AAE581 is a specific inhibitor of the cysteine protease cathepsin K. This trial is designed to provide detailed information about the effects( efficacy and safety) of AAE581 on Bone Mineral Density.</brief_summary>
	<brief_title>Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<criteria>Low spine Bone Mineral Density 0 to 1 prevalent fracture in non lumber spine History or presence of any bone disease other than osteopenia /osteoporosis Previous treatment with other antiosteoporosis agent(Wash out required) Evidence of vitamin D deficiency Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Postmenopausal women</keyword>
	<keyword>Cathepsin K inhibitor</keyword>
</DOC>